HC Wainwright Issues Negative Forecast for TSE:ONC Earnings

Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.41) per share for the year, down from their prior forecast of ($0.39). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech's Q3 2025 earnings at ($0.10) EPS.

Separately, Raymond James upgraded shares of Oncolytics Biotech to a "moderate buy" rating in a research report on Thursday.

Oncolytics Biotech Stock Performance

ONC traded up C$0.01 during trading hours on Monday, reaching C$1.39. The company's stock had a trading volume of 17,762 shares, compared to its average volume of 70,788. Oncolytics Biotech has a 52 week low of C$1.15 and a 52 week high of C$2.32. The company's 50-day moving average is C$1.50 and its 200-day moving average is C$1.45. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The firm has a market cap of C$106.84 million, a PE ratio of -3.63 and a beta of 1.35.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.